Potential of Human Nucleus Pulposus-Like Cells Derived From Umbilical Cord to Treat Degenerative Disc Disease

BACKGROUND: Degenerative disc disease (DDD) is a common spinal disorder that manifests with neck and lower back pain caused by the degeneration of intervertebral discs (IVDs). Currently, there is no treatment to cure this debilitating ailment.

OBJECTIVE: To investigate the potential of nucleus pulposus (NP)-like cells (NPCs) derived from human umbilical cord mesenchymal stem cells (MSCs) to restore degenerated IVDs using a rabbit DDD model.

METHODS: NPCs differentiated from MSCs were characterized using quantitative real-time reverse transcription polymerase chain reaction and immunocytochemical analysis. MSCs and NPCs were labeled with fluorescent dye, PKH26, and transplanted into degenerated IVDs of a rabbit model of DDD (n = 9 each). Magnetic resonance imaging of the IVDs was performed before and after IVD degeneration, and following cell transplantation. IVDs were extracted 8 wk post-transplantation and analyzed by various biochemical, immunohistological, and molecular techniques.

RESULTS: NPC derivatives of MSCs expressed known NP-specific genes, SOX9, ACAN, COL2, FOXF1, and KRT19. Transplanted cells survived, dispersed, and integrated into the degenerated IVDs. IVDs augmented with NPCs showed significant improvement in the histology, cellularity, sulfated glycosaminoglycan and water contents of the NP. In addition, expression of human genes, SOX9, ACAN, COL2, FOXF1, KRT19, PAX6, CA12, and COMP, as well as proteins, SOX9, ACAN, COL2, and FOXF1, suggest NP biosynthesis due to transplantation of NPCs. Based on these results, a molecular mechanism for NP regeneration was proposed.

CONCLUSION: The findings of this study demonstrating feasibility and efficacy of NPCs to regenerate NP should spur interest for clinical studies to treat DDD using cell therapy.

KEY WORDS: Cell therapy, Human umbilical cord mesenchymal stem cells, Intervertebral disc, Nucleus pulposus, Rabbit model, TGFβ pathway, Tissue engineering

ABBREVIATIONS: CM, conditioned medium; DAPI, 4',6-diamidino-2-phenylindole; DDD, degenerative disc disease; DM, differentiation medium; DMEM, dulbecco’s modified eagle’s medium; ECM, extracellular matrix; GM, growth medium; H&E, hematoxylin and eosin; IVD, intervertebral disc; MRI, magnetic resonance imaging; MSC, mesenchymal stem cell; NP, nucleus pulposus; NPC, nucleus pulposus-like cell; PAS, periodic acid-schiff; SEM, standard error of the mean; sGAG, sulfated glycosaminoglycan; qRT-PCR, quantitative real-time reverse transcription polymerase chain reaction

The intervertebral disc (IVD) is a fibrocartilaginous tissue that contributes to spine flexibility. Genetic-, aging-, and trauma-associated effects on IVD organization, structure, and function have been implicated in chronic lower back pain. The complex progressive disorder collectively referred to as degenerative disc disease (DDD) affects approximately 60% to 80% of people in the western countries. DDD causes substantial economic and societal burden in North America and Europe. As a result, there is a great deal of interest in elucidating the DDD process and relieving the significant societal burden associated with chronic back pain.

The IVD is composed of hydrated and gelatinous nucleus pulposus (NP), surrounding annulus fibrosus, and cartilaginous endplates. The extracellular matrix (ECM) of NP is composed of water, proteoglycans, and collagen...
that act as a shock absorber and maintain the mechanical load bearing capacity of the IVD. ECM is produced by NP cells derived from notochord precursors/progenitors, their number are decreased during the second decade of human life, thus limiting the potential to repair damaged NP. Degenerative changes in NP are characterized by the loss of cellularity and matrix integrity. IVD degeneration is irreversible and can manifest clinically as chronic neck and lower back pain.

There is no cure for DDD, and current treatments only address the symptoms rather than the cause of the disease. Patients generally seek relief using analgesics and/or physiotherapy. In severe cases, surgical procedures such as discectomy and spinal fusion are performed to mitigate pain. However, these interventions are insufficient to restore normal disc function and can further reduce the flexibility of the spine. Therefore, tissue regeneration to restore the biological and mechanical function of NP is more desirable for the treatment of symptomatic degenerated IVDs.

Several studies have attempted to use cell therapy for the regeneration of IVD with encouraging but limited success. However, in order to determine the best mode of regenerative therapy, an in depth understanding of the IVD microenvironment is required. Thus, the matrix and cell composition of the disc as well as the importance of intrinsic and extrinsic factors on the mechanical and biological function of the IVD needs to be examined. Some reports describe the potential of autologous, allogeneic, and xenogeneic chondrogenic cells and mesenchymal stem cells (MSCs) to regenerate IVDs using animal models. This study evaluated for the first time the potential of NP-like cells (NPCs) derived from human umbilical cord MSCs to restore physicochemical, histological, and molecular properties of degenerated IVDs. These results could provide a rationale and stimulus for clinical trials to treat DDD using NPCs.

METHODS

Maintenance and Culturing of MSCs

Human umbilical cord MSCs were isolated as previously reported under approved protocols (HIC# 2012–101 and IRB# 400244). MSCs were cultured and maintained in growth medium (GM) containing Dulbecco’s Modified Eagle’s Medium (DMEM) with 4500 mg/L glucose and 2 mM L-glutamine (Life technologies, Carlsbad, California), supplemented with 10% fetal bovine serum (FBS) (Aleken Biologicals, Nash, Texas), and antibiotics (0.1% gentamicin, 0.2% streptomycin, and 0.12% penicillin; Sigma Aldrich, St. Louis, Missouri).

Differentiation of MSCs into NP-Like Cells

MSCs were differentiated into NPCs using NP conditioned medium (CM) from rabbit NP cells or differentiation medium (DM) composed of a cocktail of growth factors (20 ng TGFβ1, 20 ng BMP7, 20 ng GDF5, 10 ng insulin, 100 mM dexamethasone, and 100 μM ascorbic acid).

Flow Cytometry

Flow cytometric analysis for the expression of cell surface markers (CD90-FITC/CD73-APC, CD44-FITC/CD105-APC and CD29-APC), and cell size was determined on FACS Canto II using Diva Software (Becton Dickinson, Franklin Lakes, New Jersey).

Animal Studies

Animal experiments were approved by the Animal Care Committee (Acc#AL-13-06) and Institutional Biosafety Committee (IBC#2858). Skeletally mature female New Zealand white rabbits (n = 27), aged 6 to 12 mo, weighing 3.2 to 3.5 kg, were used in this study. Experimental design consisted of 3 randomly assigned groups of 9 animals each recipient of sham (media only), NPCs, or MSCs.

Magnetic resonance imaging Evaluation

Magnetic resonance imaging (MRI) evaluations of rabbits were performed before and 2 wk after puncture to confirm the degeneration as well as 6 wk after transplantation. Rabbits were tranquilized using ketamine (40 mg/kg) and xylazine (3 mg/kg). A localizing midsagittal T2-weighted image was obtained to view the L1-2 through L5-6 using a Philips 3T Ingenia (Philips Healthcare, Best, The Netherlands). Three-mm-thick midsagittal sections were taken using T2-weighted imaging sequences to evaluate signal characteristics within the IVDs. IVD degeneration and regeneration was determined by loss or gain of signal intensity and/or loss of IVD height on the T2-weighted sequence of the disc, respectively. Quantification of IVD height was determined by measuring the distance between the upper and lower vertebral bodies in the sagittal T2-weighted MRI images at the L2-3, L3-4, and L4-5 as previously published. NP content was analyzed by measuring the mean signal intensity using Philips DICOM viewer version R3.0 SP3 (Philips Healthcare).

Transplantation of Labeled MSCs and NPCs Into the Rabbit IVD

Rabbit DDD model was developed via needle puncture as previously published. Needle punctures were performed on the 2 levels of the lumbar IVD segments at L2-3 and L4-5 to induce IVD degeneration. After 2 wk, 1 × 106 cells labeled with PKH26 dye (Sigma-Aldrich), or DMEM alone (sham) in 20 μl volume were injected into the IVD at L4-5 through a Hamilton syringe with a 22-gauge needle guided by antero-posterior and lateral fluoroscopy. L2-3 served as degenerated and L3-4 served as the healthy IVDs, and the animals were followed up to 8 wk after cell injections.

Histological Analysis

IVDs were harvested following intravenous overdose of phenobarbitone sodium (120 mg/kg, Sigma-Aldrich) euthanasia. IVDs were fixed in 10% buffered formalin overnight, decalcified using 11% formic acid, cryoprotected in 20% sucrose, and transferred to OCT for cryosectioning. Ten μm sections were stained with periodic acid-schiff (PAS), alcin blue, and hematoxylin and eosin (H&E) to evaluate the presence of glycoproteins, proteoglycan content, and cellular architecture, respectively.

Immunocytochemical Analysis

Cells and sections fixed with 4% paraformaldehyde for 10 min at room temperature, permeabilized with 0.5% triton X-100 (Sigma-
Aldrich), blocked with 2% bovine serum albumin (Sigma-Aldrich) for 1 h. Samples were then incubated in primary antibody (1:100) for 2 h, washed with Phosphate-buffered saline (PBS), followed by treatment with secondary antibody (1:200) at 37°C for 1 h, and counterstained with 4',6-diamidino-2-phenylindole (DAPI). Fluorescent images were captured using a confocal microscope (NIKON Instruments Inc, Melville, New York). Nonimmune rabbit immunoglobulin was used as the negative control in all the immunostaining experiments on the rabbit specimens. Antibodies used are listed in Table 1.

### Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction

Transcriptional analysis was performed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR). Cellular RNA was isolated using GeneJet RNA purification kit (Thermo Fisher Scientific, Waltham, Massachusetts). IVD tissue was homogenized in Trizol reagent to isolate RNA. Isolated RNA was used to synthesize cDNA using iScript kit (BioRad, Hercules, California). qRT-PCR was carried out using SsoAdvanced SYBR Green Supermix and CFX96 Real-Time PCR System (BioRad). All reactions were prepared in triplicate and normalized to reference genes, GAPDH, and ACTIN. The primer sets used for qRT-PCR are listed in Table 2.

### Statistical Analysis

Data were presented as the mean ± standard error of the mean (SEM) of triplicates. Results with a P-value ≤ .05 were considered statistically significant. Homogeneity of variance was determined with an F-test. All analyses were performed on log transformed data, using 1-way Analysis of variance (ANOVA) test and analyzed for equal variance using SPSS version 11.5 (SPSS, IBM Inc, Armonk, New York).

### Table 1. List of Primary and Secondary Antibodies Used in Immunohistochemical Staining

| Antibody | Primary | Secondary |
|----------|---------|-----------|
| ACAN     | Rabbit polyclonal | Anti-rabbit-FITC |
| COL2     | Goat polyclonal   | Anti-goat-FITC  |
| FOXF1    | Goat polyclonal   | Anti-goat-FITC  |
| SMAD2    | Rabbit polyclonal | Anti-rabbit-FITC |
| SOX9     | Goat polyclonal   | Anti-goat-FITC  |
| TGF βR2  | Rabbit polyclonal | Anti-rabbit-FITC |
| TUBB     | Goat polyclonal   | Anti-goat-FITC  |

### Table 2. List of Primer Sequences Used in qRT-PCR

| Gene     | Forward (5’-3’) | Reverse (5’-3’) | Product length |
|----------|----------------|----------------|----------------|
| hSOX9    | AGGGAAGGCACATCAAGAC | CTGTAGGGGATCTGTGTTGGG | 85 |
| hACAN    | AGCCTGCGCTCCAATGACT | GGAACACAGATGCTTTTCACC | 103 |
| hCOL2    | CTCGGTGCAAGAGATTGGAGA | CACCAAGCTTACACAGAGTTG | 252 |
| hFOXF1   | AAGGCCGCCATTCTCTCACTC | GGGGATCTGTTGGAACACTT | 63 |
| hCOMP    | AAGACAGTGTGCAGCGATG | TGTCGAGGAGTCCCTGATGT | 154 |
| hCA12    | TGGGACTGAGTGGAGAGCA | GACGACAGCAACAACCAT | 169 |
| hPAK6    | CTGTGCTTGGGAAATCGGAG | AGCCAGGTTGGGAAACACC | 103 |
| hTGFJ1   | GACCAACCATTGGTCTTCAGC | CAGGGCTTCAAAGATGGG | 156 |
| hSMURF1  | GTCCGAGGCTGAGAAGACGA | CAGCGGAACTTCCATACGCC | 166 |
| hSMURF2  | CTCCTGCGCTTCTGCAATC | GCGTGAGCCTGGGAAGCT | 128 |
| hMEKK1   | ATCTCTCCAACCACACGGGA | TGGCGCTGGTGGTTGAGAG | 200 |
| hSMAD2   | TGACGCTGAGAAGAGCCTG | GAGAACCCTACACACAGCTT | 119 |
| hSMAD3   | TAGACTTGCGGATGGGAGGG | GGGGATCTACGATTCTTCC | 123 |
| hSMAD4   | GTGATCGTGAAGAGAAGGGA | TCATTCAAACCGGGGAGTC | 84 |
| hSMAD5   | CCTTTCAACAGCCCAACACAC | TGGCAGAGGGAGGCATTACAG | 151 |
| hERK1    | TCAACACACGCTGGACCCTT | GCGTGGCTACATCTCCGTC | 102 |
| hERK2    | GTTCCCAAATGCTGACTCCAA | CTGCGGGCTGTAATACTGTC | 126 |
| hTGFβR1  | GTGACAGATGGGGCTCTGCTT | GCAATGTTGAACCTGAGTGGGA | 211 |
| hTGFβR2  | AGTGGCAGGTGGGGCCCGGAG | TCAATGGGATTGAGGGTCATT | 491 |
| hBM2P    | CGCTGTCTCTTACAGTTGGCT | GGGGGGTTGGCTCTGTGTCAT | 191 |
| hBM2P4   | CTGATGATACGCTGTCCTCC | TCAACATCTGCTTACGAG | 310 |
| hBM2P2   | CTGTGCTCTGAGGTCTTCC | TCAACATCTGCTTACGAG | 90 |
| hFOXC2   | CGGCTAAGGCTGATTGGA | GGAACGCTTTGACTAGTA | 123 |
| hNODAL   | TGCTGGAGGAGGAGAGGAGGAGGAGGAC | GCAACACAGATGGTGGGAGGAC | 75 |
| hFGF5    | ATCAGACCTCTCTCTTCTCTG | ACAGACAGACAGACAGAC | 119 |
| hFGF10   | TGCTAAGCTGCTGCTCCAT | CCCAAAGGGGATTTCCATTTACG | 101 |
| hGAPDH   | ACAACTTGGTACAGCTGGGAGG | GCCATCGCACAGATCTTC | 170 |
| hACTIN   | ATATCGGCACACACCTCTAC | ATAGCAACAGCCTGGTATTACCA |
RESULTS

Differentiation of MSCs into NP-like Cells

The results depicted in Figure 1A showed that MSCs differentiated in CM had an elongated morphology, whereas DM cultured cells were large and flat (Figure 1A). The differentiated cells stained with alcian blue indicating the presence of glycoproteins in the ECM (Figure 1B). The fact that matrix protein expression was higher in cells differentiated in DM suggest that it is more inductive than CM. DM-differentiated cells expressed chondrogenic-specific genes, SOX9, ACAN, and COL2, as well as NP-specific markers, FOXF1, PAX6, CA12, and COMP, with poorly expressed KRT19 (Figure 1C). They also expressed proteins, SOX9, ACAN, COL2, and FOXF1 (Figures 1D and 1E). The differentiation efficiency of MSCs into NPCs was 36% to 45% as determined by a decrease in the percentage of cells positively expressing MSC-specific surface markers (Figures 1F and 1G). These cells also had larger cell size than MSCs (Figure 1H). Based on the ability of MSC derivatives to produce ECM and express NP-specific markers, they were denoted NPCs.

Transplantation of NP-like Cells in the Degenerated IVDs

NPCs labeled with PKH26 with >95% labeling efficiency (Figure 2A) and >95% cell viability (Figure 2B) were transplanted into the degenerated IVDs, L4-5, using a Hamilton syringe into the central NP region of the IVDs. IVDs displayed degeneration 2 wk after puncture, and a progressive loss of disc height was confirmed by MRI analysis 6 wk post-transplantation (Figure 2C). Disc height improved in NPC-transplanted IVDs by 25% and 38% (P < .05) as compared to the degenerated and sham IVDs, respectively. NPC-treated IVDs had only 12% less disc height when compared with healthy IVDs (Figure 2D). In addition, there was a significant increase in NP T2-weighted MRI signal intensity of NPC-treated IVDs compared to the degenerated disc and sham (Figures 2C and 2E).

Physicochemical Evaluation of IVDs

The physical content of the NP was significantly reduced in degenerated and sham IVDs as compared to healthy discs. In fact, degenerated and sham IVDs were calcified and displayed partial loss of NP. Degenerated IVDs that received NPCs showed significant improvement in NP content with concomitant increase in sulfated glycosaminoglycan (sGAG) and water content when compared with sham IVDs (Figures 3A-3C). After 8 wk, sGAG decreased 38% and 53% in degenerated and sham IVDs, respectively. The sGAG content in the NPCs-treated IVDs improved to 91% compared to sham and was similar to healthy IVDs (Figure 3B). Likewise, water content of NP in transplanted IVDs was not significantly different from healthy IVDs (Figure 3C).

Postharvested Histology of Rabbit IVDs

Histological analysis of IVDs was performed to determine the presence of ECM proteins as well as cellular and structural integrity. PAS staining indicated fissured morphology with less ECM content in the NP of the degenerated compared to the healthy IVDs (Figure 3D). In contrast, ECM content was improved and uniformly distributed in the degenerated IVDs that received NPCs. Alcian blue staining also showed improvement in the distribution of glycoproteins and cellularity in IVDs transplanted with NPCs than that of degenerated or sham IVDs (Figure 3D). In fact, NPC-transplanted IVDs appeared similar to the healthy IVDs. H&E staining also showed that unlike degenerated IVDs, NPC-transplanted IVDs showed improvement in structural and cellular integrity (Figure 3D).

Immunotracking and Expression of Human-Specific Markers

PKH26-labeled cells were localized in the NP region of the transplanted but not in sham IVDs (Figure 4A). Both transplanted MSCs and NPCs survived in rabbit IVDs. While MSCs remained localized at the transplantation site, NPCs were more dispersed and integrated into the host NP. Expression of chondrogenic genes, SOX9, ACAN, COL2, and NP genes, FOXF1, KRT19, PAX6, CA12, and COMP, were significantly upregulated in NPC compared to MSC-transplanted IVDs (Figure 4B). In fact, the expression of these genes was significantly higher in NPCs following transplantation suggesting that the IVD microenvironment played a role in upregulating the expression of NP-specific genes. Further analysis of IVDs transplanted with MSCs showed high expression of CD90 but lower levels of SOX9, ACAN, and COL2 (Figure 4C). IVDs transplanted with NPCs expressed high levels of both chondrogenic proteins, SOX9, ACAN, and COL2, and the NP protein FOXF1 (Figure 4C). As expected, human housekeeping protein TUBB was expressed in IVDs transplanted with MSCs and NPCs. These results showed the colocalization of human proteins and PKH26 labeling in the NP region of IVDs. Quantification of the mean fluorescent intensity in Figure 4D showed that the intensity of FOXF1 was not detectable in the case of MSC-treated IVDs.

To explore the underlying molecular mechanism involved in the ability of NPCs to regenerate NP in Vivo, various signaling pathways that play a role in the differentiation process were investigated. Transcriptional analysis of the IVDs showed that TGFβ1, TGFβ2, SMURF1, SMURF2, MEKK1, SMAD2, SMAD3, SMAD4, SMAD5, ERK1, and ERK2 were significantly upregulated and BMP2, BMP4, and BMP7 were not expressed in the transplanted IVDs as compared to the NPCs in Vitro (Figure 5A). Immunocytochemical analysis of NPC-transplanted IVDs revealed the expression of human-specific proteins, TGFβR2 and SMAD2 (Figure 5B) but not TGFβR1 and BMPR2 (not shown). These results indicate that TGFβ1/Smad signaling potentially played a role in the ECM production and NP regeneration via TGFβ1 but not the BMP2/4/7 members of this pathway (Figure 5C).
FIGURE 1. Differentiation of human umbilical cord mesenchymal stem cells (MSCs) into NP-like cells (NPCs) in vitro. **A**, Phase contrast images of the morphology of MSCs in GM and differentiated cells in CM and DM after 2 wk. **B**, Alcian blue staining of the NPCs derived using both media displaying the presence of ECM. Scale bars represent 100 μm (magnification: 4×). **C**, Comparison of the expression of NP-specific genes SOX9, aggrecan (ACAN), collagen 2 (COL2), FOXF1, KRT19, PAX6, CA12, and COMP between the NPCs derived from CM and DM, using qRT-PCR. Gene expression was normalized to GAPDH and ACTIN, and error bars represent the SEM of triplicate experiments. **D**, Immunocytochemical staining of the NP-specific proteins SOX9, ACAN, COL2, and FOXF1 between the NPCs derived from 2 different media. The nuclei of the cells are stained with DAPI (blue) and the expressions of proteins are stained in green. Scale bars represent 100 μm (magnification: 10×). **E**, Quantitative analysis of fluorescent intensities of NP proteins using Image J software. **F**, Flow cytometric analysis of MSCs differentiated into NPCs showing a decrease in selected MSC surface markers, CD90/CD73, CD44/CD105 and CD29. **G**, Quantification of the MSC surface markers listed in **F**. **H**, Flow cytometric plots displaying significant increase in the cell size of NPCs compared to MSCs.
DISCUSSION

We have previously shown that mouse ESC-derived chondroprogenitors exhibited promising results in the regeneration of the degenerated IVD. However, human ESC-based therapies face ethical and moral challenges as well as pose the risk of teratoma formation. MSCs from adult sources have been tested for their therapeutic potential to treat DDD, and however, isolation of MSCs from adult sources requires invasive procedures, and they have limited proliferation and differentiation potential due to aging. Several studies have been attempted to investigate the use of perinatal MSCs to regenerate IVDs, which are more advantageous since they can be obtained noninvasively in large numbers. Furthermore, they display a lower risk of graft vs host disease compared to bone marrow MSCs. Nevertheless, donor cells/tissue matching with the recipient would be beneficial. We hypothesized that MSCs differentiated into the chondrogenic lineage could be more effective in regenerating NP, since chondroprogenitors are capable of producing sGAG and glycoproteins in animal models.

The results showed that MSCs differentiated in DM produced ECM and expressed NP-specific genes and proteins. This is supported by the studies that TGFβ and IGF, components of DM promote differentiation of MSCs into NP lineage.

In this study, we differentiated MSCs into NPCs to test their efficacy for regeneration of damaged NP using the rabbit model for DDD. Histological analysis provided evidence of increase in the amount and distribution of ECM, proteoglycans, and glycoproteins as well as enhanced cellularity in the NP of the IVDs transplanted with NPCs. Furthermore, improvement in the structural integrity of NP was observed. These results are in agreement with other studies that showed improvements in cellularity and glycoproteins using cell therapy in IVDs of animal models. In addition, the transplanted IVDs showed a significant increase in the amount and distribution of sGAG in the NP, suggesting that the human NPCs xenogenetically influenced the metabolic activity of the rabbit IVDs. In our animal model, no Modic changes were observed in the degenerated or regenerated IVDs, perhaps because Modic changes are usually associated with chronic degeneration of the IVD. A long-term study would be needed to explore the effects of cell therapy on Modic changes.

Transplantation of NPCs helped improve the disc height and physiochemical characteristics of the NP as determined by MRI analysis. The fact that degenerated and sham IVDs showed that calcification and partial loss of NP was inhibited by NPC treatment provides preliminary indication of halting the degeneration process. The functional and metabolic restoration of the NP depends entirely on sGAG, NP content, and disc hydration. Quantitative analysis of the NP of the rabbit IVDs revealed that sGAG, water content, and physical size of the NP were significantly improved due to augmentation with NPCs.

Expression of human specific markers, SOX9, ACAN, COL2, and FOXF1 in the NP of the treated IVDs, suggested that the transplanted human NPCs were viable and functionally active in the rabbit IVD. In fact, expression of acknowledged NP-specific genes, FOXF1, KRT19, PAX6, CA12, and COMP was higher in the NP tissue of the IVDs transplanted with NPCs when compared to MSCs. Interestingly, KRT19 was found to be poorly expressed in NPCs in Vitro as discussed above. KRT19 is known to be involved in structural integrity; therefore, it may have a role in the histological improvement of the NP in Vivo. These results suggest a possible role of microenvironment of IVDs in the survival and activity of the NPCs.

Our results also showed increased transcript levels of several intermediates of the TGFβ/Smad pathway, TGFβ1, TGFβ2, SMURF1, SMURF2, MEKK1, SMAD2, SMAD3, SMAD4, SMAD5, ERK1, and ERK2, which could be the reason for the production of enhanced levels of sGAG and water contents as well as ECM proteins in the IVDs recipient of NPCs. Because TGFβ1 was not expressed in the NP of IVDs transplanted with NPCs, TGFβ signaling appeared to occur by the binding of TGFβ1 to TGFβR2 that triggered the upregulation of SMADs. It has been previously reported that TGFβ1 gene therapy increased proteoglycan synthesis. These results are supported by the reports that the members of the TGFβ superfamily play an important role in chondrogenic differentiation and the expression of TGFβ is decreased in IVD cells upon...
FIGURE 3. Physicochemical and histological analysis of the rabbit lumbar spine IVDs treated with human NPCs. A, Photographic images of the extracted IVDs displaying NP content (red circle) of the healthy (L3-4), degenerated (L2-3), sham (L4-5), and treated with NPCs (L4-5) IVDs. B and C, Bar graphs showing comparative quantification of the sGAG and water content in the IVDs, respectively. D, Cryosections of the extracted IVDs stained with PAS and alcian blue, and counterstained with nuclear fast red stain as well as H&E displaying presence of glycoproteins, ECM proteins, and the intracellular morphology, respectively. All scale bars represent 100 μm (magnification: 4×). The inserts represent higher magnification, 100 μm (magnification: 10×). The images clearly indicate that the treated IVDs that received the NPCs appear to be aiding in regeneration or maintenance of the degenerated disc compared to the puncture.
FIGURE 4. Post-transplantation analysis of molecular analysis of IVDs. A, Tracking of the PKH26-labeled MSCs and NPCs in the cryosections of the IVDs indicated the presence of transplanted cells in the treated IVDs. Scale bars represent 100 μm (magnification: 10×). B, Post-transplantation comparative analysis of IVDs treated with human MSCs and NPCs for the expression of human chondrogenic specific genes, SOX9, ACAN, COL2, and NP-specific genes, FOXF1, KRT19, PAX6, CA12, and COMP, using qRT-PCR. C, Immunohistochemical analysis of the IVDs treated with MSCs and NPCs, respectively, showed expression of human specific-NP proteins, SOX9, ACAN, COL2, FOXF1, and TUBB. Red, blue, and green colors represent the cell labeling dye PKH26, DAPI staining the nuclei, and antibodies labeling human proteins, respectively. Scale bars represent 100 μm (magnification: 10×). D, Quantification of mean fluorescent intensities of SOX9, ACAN, COL2, FOXF1, TUBB expression in MSCs and NPCs transplanted in IVDs using Image J software.
REGENERATION OF IVD BY NPCs DERIVED FROM UMBILICAL CORD MSCS

FIGURE 5. Molecular analysis and proposed signaling pathway involved in IVD regeneration in Vivo. A, Expression of genes involved in TGFβ/Smad pathway, TGFβ1, TGFβR1, TGFβR2, BMP2, BMP4, BMPR2, SMURF1, SMURF2, MEKK1, SMAD2, SMAD3, SMAD4, SMAD5, ERK1, ERK2, FOXC2, NODAL, GDF5, and GDF10 using qRT-PCR. Gene expression was normalized to GAPDH and ACTIN and error bars represent the SEM of triplicate experiments. B, Translational analysis of the selected human-specific proteins, SMAD2 and TGFβR2 of TGFβ/Smad pathway. Merged images of the red, blue, and green colors representing the cell labeling dye PKH26, DAPI staining the nuclei, and antibodies labeling human proteins, respectively. All scale bars represent 100 μm (magnification: 10×). C, Schematic diagram of the proposed pathway facilitating upregulation of NP differentiation transcription factors. The solid line indicates the genes tested in this study, whereas the dashed lines represent the speculated mechanism.

aging. Based on these observations, a molecular mechanism involved in the functioning of NPCs and regeneration of NP in the IVDs via TGFβ1 is proposed. However, additional experiments are warranted to determine the signaling mechanism.

Due to the fact that NP is an avascular tissue, no inflammatory response was observed in the transplanted IVDs. Furthermore, perinatal stem cells have low risk of rejection-making NPCs derived from umbilical cord MSCs an ideal source for treating DDD in humans.

Limitations

The results of this study provide more compelling evidence for the efficacy of MSC derivatives for devising strategies to treat not only DDD but also other degenerative diseases. However, this study was carried out using a limited number of animals and further blinded investigations utilizing a greater number of animals or use of a large animal model would be helpful. Nevertheless, the significance of our results is strengthened by a recent clinical study, reporting treatment of 2 patients with chronic discogenic low back pain using umbilical cord cells resulting in alleviation of pain and functional improvement.

CONCLUSION

This study demonstrates for the first time that NPC-derived MSCs were functionally active in the rabbit IVDs and showed the potential to repair or regenerate the degenerated NP tissue. The results further provide the impetus and basis for clinical trials for treating DDD using MSC-derived NPCs.
Disclosures

Dr Khan was supported by the Dr Panjwani Center for Molecular Medicine and Drug Research, Pakistan. The study was supported by the Michigan Head and Spine Institute, OU-WB ISCRM, and Oakland University. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

REFERENCES

1. Chou AI, Reza AT, Nicoll SB. Distinct intervertebral disc cell populations adopt similar phenotypes in three-dimensional culture. Tissue Eng Part A. 2008;14(12):2079-2087.
2. Sobajima S, Kim JS, Gilbertson LG, Kang JD. Gene therapy for degenerative disc disease. Gene Ther. 2004;11(4):390-401.
3. Brinijki W, Luetmer PH, Comstock B, et al. Systematic literature review of imaging features of spinal degeneration in asymptomatic populations. Am J Neuroradiol. 2015;36(8):811-816.
4. Whitehurst DG, Bryan S, Lewis M, Hill J, Hay EM. Exploring the cost-utility of stratified primary care management for low back pain compared with current best practice within risk-defined subgroups. Ann Rheum Dis. 2012;71(11):1796-1802.
5. Rutges J, Creemers LB, Dhert W, et al. Variations in gene and protein expression in human nucleus pulposus in comparison with annulus fibrosus and cartilage cells: potential associations with aging and degeneration. Osteoarthr Cartilage. 2010;18(3):416-423.
6. Showalter BL, Beckstein JC, Martin JT, et al. Comparison of animal discs used in disc research to human lumbar disc: torsion mechanics and collagen content. Spine. 2012;37(15):E900-E907.
7. Kim KW, Lim TH, Kim JG, Jeon ST, Masuda K, An HS. The origin of chondrocytes in the nucleus pulposus and histologic findings associated with the transition of a notochordal nucleus pulposus to a fibrocartilaginous nucleus pulposus in intact rabbit intervertebral discs. Spine. 2003;28(10):982-990.
8. Wang YH, Yang B, Li WL, Li JM. Effect of the mixture of bone marrow mesenchymal stromal cells and annulus fibrosus cells in repairing the degenerative discs of rabbits. Genet Mol Res. 2015;14(1):2356-2373.
9. Rodrigues-Pinto R, Richardson SM, Hoyland JA. Identification of novel nucleus pulposus markers: interspecies variations and implications for cell-based therapies for intervertebral disc degeneration. Bone Joint Res. 2013;2(8):169-178.
10. Clourier J, Pot-Vaucel M, Grimaldi G, et al. Characterization of the age-dependent intervertebral disc changes in rabbit by correlation between MRI, histology and gene expression. BMC Musculoskelet Disord. 2011;12(1):147.
11. Chan SC, Burki A, Bolen HM, Benneker LM, Gantenbein-Ritter B. Papain-induced in vitro disc degeneration model for the study of injectable nucleus pulposus therapy. Spine J. 2015;15(3):273-283.
12. Alvin MD, Qureshi S, Klineberg E, et al. Cervical degenerative disease: systematic review of economic analyses. Spine. 2014;39(22 suppl 1):S53-S66.
13. Wan Y, Feng G, Shen HF, Laurencin CT, Li X. Biphasic scaffold for annulus fibrosus tissue regeneration. Biomaterials. 2008;29(6):643-652.
14. Leung VY, Chan D, Cheung KM. Regeneration of intervertebral disc by bone marrow mesenchymal stem cells: potentials, limitations, and future direction. Eur Spine J. 2008;17:S4-17.
15. Bowles RD, Gehbhard HH, Harel R, Bonassar LJ. Tissue-engineered disc cells produce new matrix, maintain disc height, and restore biomechanical function to the rodent spine. Proc Natl Acad Sci. 2011;108(32):13106-13111.
16. Drizen D, Rosner J, Aviolas P, Acosta F. Stem cell therapy for degenerative disc disease. Adv Orthop. 2012;2012:1-8.
17. Kandel R, Roberts S, Urban JP. Tissue engineering and the intervertebral disc: the challenges. Eur Spine J. 2008;17(S4):480-491.
18. Hennekson HB, Svanvik T, Jonsson M, et al. Transplantation of human mesenchymal stem cells into intervertebral discs in a xenogeneic porcine model. Spine. 2009;34(2):141-148.
19. Oehme D, Goldschlager T, Ghosh P, Rosenfeld JV, Jenkins G. Cell-based therapies used to treat lumbar degenerative disc disease: a systematic review of animal studies and human clinical trials. Stem Cells Int. 2015;2015:1-16.
20. Sakai D, Mochida J, Yamamoto Y, et al. Transplantation of mesenchymal stem cells embedded in Atelocollagen® gel to the intervertebral disc: a potential therapeutic model for disc degeneration. Biomaterials. 2003;24(20):3531-3541.
21. Sheikh H, Zakharian K, De La Torre RP, et al. In vivo intervertebral disc regeneration using stem cell-derived chondroprogenitors. J Neurosurg Spine. 2009;10(3):265-272.
22. Wei JN, Cai F, Wang F, et al. Transplantation of CXCRI4 overexpressed mesenchymal stem cells augments regeneration in degenerated intervertebral discs. DNA Cell Biol. 2016;35(5):241-248.
23. Zhang Y, Tao H, Gu T, et al. The effects of human Wharton’s jelly cell transplantation on the intervertebral disc in a canine disc degeneration model. Stem Cell Res Ther. 2015;6(1):154.
24. Richardson SM, Kalamegam G, Pushparaj PN, et al. Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration. Methods. 2016;99:69-80.
25. Meisel HJ, Sidolia V, Ganey T, Minkus Y, Hutton WC, Alasevic OJ. Clinical experience in cell-based therapeutics: disc chondrocyte transplantation A treatment for degenerated or damaged intervertebral disc. Biomol Eng. 2007;24(1):5-21.
26. Martia G, Campanella R, Navone SE, et al. Potential use of human adipose mesenchymal stromal cells for intervertebral disc regeneration: a preliminary study on biglycan-deficient murine model of chronic disc degeneration. Arthritis Res Ther. 2014;16(5):457.
27. Leckie SK, Sowa GA, Bechara BP, et al. Injection of human umbilical tissue-derived cells into the nucleus pulposus alters the course of intervertebral disc degeneration in vivo. Spine J. 2013;13(3):263-272.
28. Jeong JH, Lee JH, Jin ES, Min JK, Jeon SR, Choi KH. Regeneration of intervertebral discs in a rat disc degeneration model by implanted adipose-tissue-derived stromal cells. Acta Neurochir. 2010;152(10):1771-1777.
29. Ghosh P, Moore R, Vernon-Roberts B, et al. Immunoselected STRO-3 + mesenchymal precursor cells and restoration of the extracellular matrix of degenerate intervertebral discs. J Neurourol Surg. 2012;16(5):479-488.
30. Chen HJ, Kim YS, Kim BK, et al. Transplantation of human adipose-derived stem cells in a rabbit model of traumatic degeneration of lumbar discs. World Neurosurg. 2012;78(3-4):364-371.
31. Beerravolu N, Brougham J, Khan I, McKee C, Perez-Cruet M, Chaudhry RG. Human umbilical cord derivatives regenerate intervertebral disc. J Tiss Eng Regen Med. 2016;12(1):e579-e591.
32. Ahn J, Park EM, Kim BJ, et al. Transplantation of human Wharton’s jelly-derived mesenchymal stem cells highly expressing TGFβ1 receptors in a rabbit model of disc degeneration. Stem Cell Res Ther. 2015;6(1):190.
33. Alghamdi S, Khan I, Beerravolu N, et al. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. Stem Cell Res Ther. 2016;7(1):22.
34. Beerravolu N, Khan I, McKee C, et al. Isolation and comparative analysis of potential stem/progenitor cells from different regions of human umbilical cord. Stem Cell Res. 2016;16(3):696-711.
35. Korecki CL, Tabous JM, Tian RS, Iatridis JC. Notochordal cell conditioned medium stimulates mesenchymal stem cell differentiation toward a young nucleus pulposus phenotype. Stem Cell Res Ther. 2010;1(2):696-711.
36. Luoma K, Vehmas T, Riihimaki H, Raininko R. Disc height and signal intensity of the nucleus pulposus on magnetic resonance imaging as indicators of lumbar disc degeneration. Spine. 2001;26(6):680-686.
37. Lo B, Parham L. Ethical issues in stem cell research. Endocr Res. 2009;30(3):204-213.
38. Espinoza N, Peterson M. How to depolarise the ethical debate over human embryonic stem cell research (and other ethical debates too!). J Med Ethics. 2012;38(8):496-500.
39. Teshendorff AE, Jones A, Fiegler H, et al. Epigenetic variability in cells of normal cytotaxy is associated with the risk of future morphological transformation. Genome Med. 2012;4(3):24.
40. Liu L, Cheung TH, Charville GW, et al. Chromatin modifications as determinants of muscle stem cell quiescence and chronological aging. Cell Rep. 2013;4(1):189-204.
41. Bentvenga A, Miloso M, Riva, et al. DNA methylation changes during cultures in vitro propagation of human mesenchymal stem cells: implications for their genomic stability? Stem Cells International. 2013;2013.
42. Pang X, Yang H, Peng B. Human umbilical cord mesenchymal stem cell transplantation for the treatment of chronic discogenic low back pain. Pain Physician. 2014;17(4):E525-E530.
43. Hua J, Qiu P, Zhu H, Cao H, Wang F, Li W. Multipotent mesenchymal stem cells (MSCs) from human umbilical cord:Potential differentiation of germ cells. Afr J Biochem Res. 2011;5(4):1-9.
REGENERATION OF IVD BY NPCS DERIVED FROM UMBILICAL CORD MSCS

44. Arufe MC, De la Fuente A, Fuentes I, Toro FJ, Blanco FJ. Umbilical cord as a mesenchymal stem cell source for treating joint pathologies. World J Orthop. 2011;2(6):45-50.

45. Vadala G, Russo F, Ambrosio L, Loppini M, Denaro V. Stem cells sources for intervertebral disc degeneration. World J Stem Cells. 2016;8(5):185-201.

46. Acosta FL, Jr, Metz L, Adkisson HD, et al. Porcine intervertebral disc repair using allogeneic juvenile articular chondrocytes or mesenchymal stem cells. Tissue Eng Part A. 2011;17(23-24):3045-3055.

47. Zhengjun B, Jianhua S. Development of a KLD-12 polypeptide/TGF-β1-tissue scaffold promoting the differentiation of mesenchymal stem cell into nucleus pulposus-like cells for treatment of intervertebral disc degeneration. Int J Clin Exp Pathol. 2015;8(2):1093-1103.

48. Gupta MS, Cooper ES, Nicoll SB. Transforming growth factor-beta 3 stimulates cartilage matrix elaboration by human marrow-derived stromal cells encapsulated in photocrosslinked carboxymethylcellulose hydrogels: potential for nucleus pulposus replacement. Tissue Eng Part A. 2011;17(23-24):2903-2910.

49. Colombier P, Clouer J, Boyer C, et al. TGF-beta1 and GDF5 act synergistically to drive the differentiation of human adipose stromal cells toward nucleus pulposus-like cells. Stem Cells. 2016;34(3):653-667.

50. Song K, Gu T, Shuang F, et al. Adipose-derived stem cells improve the viability of nucleus pulposus cells in degenerated intervertebral discs. Med Sci Monit. 2015;12(3):4664-4668.

51. Shim EK, Lee JS, Kim DE, et al. Autogenous mesenchymal stem cells from the vertebral body enhance intervertebral disc regeneration via paracrine interaction: an in vitro pilot study. Cell Transplant. 2016;1948-1957.

52. Strassburg S, Richardson SM, Freemont AJ, Hoyland JA. Co-culture induces mesenchymal stem cell differentiation and modulation of the degenerate human nucleus pulposus cell phenotype. Regen Med. 2016;5(5):701-711.

53. Parmeswar D, Schek M, Abbott RD, Ballif BA, Godburn KE, Iatridis JC. Notochordal conditioned media from tissue increases proteoglycan accumulation and promotes a healthy nucleus pulposus phenotype in human mesenchymal stem cells. Arthritis Res Ther. 2011;13(3):R81.

54. Han C, Wang T, Jiang HQ, et al. An animal model of modic changes by embedding autogenous nucleus pulposus inside subchondral bone of lumbar vertebrae. Sci Rep. 2016;6(1):35102.

55. Erwin WM, Hood KE. The cellular and molecular biology of the intervertebral disc: a clinician’s primer. J Can Chiropr Assoc. 2014;58(3):246-257.

56. Minogue BM, Richardson SM, Zeef LA, Freemont AJ, Hoyland JA. Characterization of the human nucleus pulposus cell phenotype and evaluation of novel marker gene expression to define adult stem cell differentiation. Arthritis Rheum. 2010;62(12):3695-3705.

57. Han XB, Zhang YL, Li HY, et al. Differentiation of human ligamentum flavum stem cells toward nucleus pulposus-like cells induced by coculture system and hypoxia. Spine. 2015;40(12):E665-E674.

58. Pattappa G, Li Z, Peroglio M, Witsøe N, Alini M, Grad S. Diversity of intervertebral disc cells: phenotype and function. J Anat. 2012;222(6):480-496.

59. Molinos M, Almeida CR, Caldeira J, Canha C, Goncalves RM, Barbosa MA. Inflammation in intervertebral disc degeneration and regeneration. J R Soc Interface. 2015;12(104):20141191.

60. Maerz T, Herkowitz H, Baker K. Molecular and genetic advances in the regeneration of the intervertebral disc. Surg Neurol Int. 2013;4(suppl 2):20141191-20141191.

61. Rodrigues-Pinto R, Richardson SM, Hoyland JA. Identification of novel nucleus pulposus markers: interspecies variations and implications for cell-based therapies for intervertebral disc degeneration. Bone Joint Res. 2015;2(8):169-178.

62. Sakai D. Future perspectives of cell-based therapy for intervertebral disc disease. Eur Spine J. 2008;17(S4):452-458.

Acknowledgments

We acknowledge Dr S. Chintala (Institute for Genetic Medicine, Keck Medical School, University of Southern California) for help with confocal microscopy and Dr H. Qu (Oakland University) for his evaluation of the statistical analysis. We also thank E. Morrison, M. McGonagle, and H. Brzezinski for help with the animal care as well as Dr Y. Seonghwan and J. Wloch for MRI assistance.

COMMENT

The current published study is an extremely important piece of work demonstrating that human-derived umbilical mesenchymal stem cells that are grown in differentiated medium express specific nucleus pulposus genes and proteins that ultimately can repair the damaged nucleus pulposus in a rabbit model of degenerative disc disease. The study end-points are comprehensive and include histological and imaging criteria of success.

The above animal studies are critical elements required to move stem cell injections to treat degenerative disc disease in humans (a ubiquitous disease) in a non-invasive fashion. Due to the relative avascular nature of the nucleus pulposus – the current study suggests that immune rejection from MHC disparities will pose less of a problem. We look forward to more data from this group as this exciting area of research moves forward.

Allan D. Levi
Miami, Florida